VEGFA and ovarian cancer: In our study, we found that MSCs could deliver miR-424 into ovarian cancer cells to target MYB, which further inhibited the expression of VEGF and also endothelial cell proliferation, migration as well as tube formation, thereby suppressing the angiogenesis of ovarian cancer.